The trial was small, involving only 45 patients in total.
What they found though was that after six weeks of treatment with Tykerb, they saw tumor regression.
Tykerb reduced the number of cancer-causing stem cells from 10.6% to 4.7%
This could open up the chance of Tykerb becoming a way to treat and prevent breast cancer development and recurrence.
The data was presented at the European Breast Cancer Conference in Berlin.
Glaxo stated that the stem cell treatment and technology is still very early though.
In the future, researchers hinted that targeting stem cells may be a better way to fight breast cancer.